Clinical Trial Update: Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations [Phase 2]

View source ↗

Summary

Phase 2 trial of PF-06649751 in Parkinson's disease patients with motor fluctuations was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• PF-06649751 (PF-06649751)

Snippet

Sponsor: Pfizer | Conditions: Parkinson Disease | Phase 2 | Status: TERMINATED | Results posted: 2018-12-24